Drug Profile
Research programme: peptide therapeutics - SymThera
Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator SymThera
- Class Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for research development in Duchenne muscular dystrophy in USA (Parenteral)
- 02 Nov 2016 Early research in Duchenne muscular dystrophy in USA (Parenteral) before November 2016 (SymThera website, November 2016)